Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark C Markowski

Showing results (1-10 of 72) with videos related to

Pageof 8
Sort By:
Cancer Treatment Reviews|October 11, 2016
Early use of chemotherapy in metastatic prostate cancerMark C Markowski, Michael A Carducci
Nature Reviews. Urology|May 5, 2026
Managing patients with recurrent prostate cancer who refuse ADTKerry R Schaffer, Mark C Markowski
Prostate Cancer and Prostatic Diseases|May 19, 2021
The interplay of microbiota and hormone regulation in men with prostate cancerMark C Markowski, Karen S Sfanos
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2020
<i>BRCA1</i> Versus <i>BRCA2</i> and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?Mark C Markowski, Emmanuel S Antonarakis
Oncoscience|June 2, 2018
Germline genetic testing in prostate cancer - further enrichment in variant histologies?Mark C Markowski, Emmanuel S Antonarakis
Expert Review of Anticancer Therapy|June 11, 2020
PARP inhibitors in prostate cancer: time to narrow patient selection?Mark C Markowski, Emmanuel S Antonarakis
Asian Journal of Andrology|April 14, 2015
Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancerMark C Markowski, Kenneth J Pienta
Nature Reviews. Urology|June 5, 2020
Advanced renal cell carcinoma and COVID-19 - a personal perspectiveYasser Ged, Mark C Markowski, Phillip M Pierorazio
Cancer Research|September 2, 2008
Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1Mark C Markowski, Cai Bowen, Edward P Gelmann
The Prostate|March 31, 2022
Bipolar androgen therapy (BAT): A patient's guideSamuel Denmeade, Emmanuel S Antonarakis, Mark C Markowski
Pageof 8

Showing results (1-10 of 72) with videos related to

Sort By:
Pageof 8
Cancer Treatment Reviews|October 11, 2016
Early use of chemotherapy in metastatic prostate cancerMark C Markowski, Michael A Carducci
Nature Reviews. Urology|May 5, 2026
Managing patients with recurrent prostate cancer who refuse ADTKerry R Schaffer, Mark C Markowski
Prostate Cancer and Prostatic Diseases|May 19, 2021
The interplay of microbiota and hormone regulation in men with prostate cancerMark C Markowski, Karen S Sfanos
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2020
<i>BRCA1</i> Versus <i>BRCA2</i> and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?Mark C Markowski, Emmanuel S Antonarakis
Oncoscience|June 2, 2018
Germline genetic testing in prostate cancer - further enrichment in variant histologies?Mark C Markowski, Emmanuel S Antonarakis
Expert Review of Anticancer Therapy|June 11, 2020
PARP inhibitors in prostate cancer: time to narrow patient selection?Mark C Markowski, Emmanuel S Antonarakis
Asian Journal of Andrology|April 14, 2015
Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancerMark C Markowski, Kenneth J Pienta
Nature Reviews. Urology|June 5, 2020
Advanced renal cell carcinoma and COVID-19 - a personal perspectiveYasser Ged, Mark C Markowski, Phillip M Pierorazio
Cancer Research|September 2, 2008
Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1Mark C Markowski, Cai Bowen, Edward P Gelmann
The Prostate|March 31, 2022
Bipolar androgen therapy (BAT): A patient's guideSamuel Denmeade, Emmanuel S Antonarakis, Mark C Markowski
Pageof 8